Relay Therapeutics (RLAY) Return on Sales (2021 - 2026)

Relay Therapeutics (RLAY) has 6 years of Return on Sales data on file, last reported at 0.24% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.24%, down 14.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.25% (up 18.0% YoY), and the FY2025 annual result was 0.18%, up 16.0% from the prior year.
• Return on Sales eased to 0.24% in Q1 2026 per RLAY's latest filing, from 0.08% in the prior quarter.
• Over five years, Return on Sales peaked at 834.96% in Q4 2023 and troughed at 8.28% in Q2 2023.
• A 5-year average of 47.71% and a median of 0.35% in 2024 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2023 and 2024: Return on Sales soared 83763 bps in 2023, then slumped 83530 bps in 2024.
• A 5-year view of Return on Sales shows it stood at 2.67% in 2022, then surged by 31405 bps to 834.96% in 2023, then plunged by 100 bps to 0.34% in 2024, then soared by 77 bps to 0.08% in 2025, then tumbled by 211 bps to 0.24% in 2026.
• Business Quant data shows RLAY's Return on Sales at 0.24% in Q1 2026, 0.08% in Q4 2025, and 0.36% in Q3 2025.